Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ 456 Cr.
- Current Price ₹ 798
- High / Low ₹ 1,584 / 763
- Stock P/E 72.5
- Book Value ₹ 688
- Dividend Yield 0.63 %
- ROCE 6.45 %
- ROE 4.39 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.16 times its book value
Cons
- The company has delivered a poor sales growth of 1.52% over past five years.
- Company has a low return on equity of 12.5% over last 3 years.
- Earnings include an other income of Rs.28.6 Cr.
- Dividend payout has been low at 13.2% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
287 | 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 362 | 345 | 327 | |
254 | 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 315 | 342 | 335 | |
Operating Profit | 33 | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 | 3 | -9 |
OPM % | 11% | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% | 1% | -3% |
1 | 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 58 | 30 | 29 | |
Interest | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
Depreciation | 11 | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 | 8 |
Profit before tax | 18 | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 97 | 25 | 12 |
Tax % | 32% | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | 22% | 32% | |
13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 17 | 6 | |
EPS in Rs | 22.02 | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 132.15 | 30.14 | 11.02 |
Dividend Payout % | 23% | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% | 17% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 2% |
3 Years: | 3% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | -2% |
3 Years: | -20% |
TTM: | -91% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 14% |
3 Years: | 13% |
1 Year: | -49% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 12% |
3 Years: | 12% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 85 | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 | 387 |
42 | 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 3 | 12 | |
66 | 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 112 | 107 | |
Total Liabilities | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 |
67 | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 99 | |
CWIP | 3 | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 2 |
Investments | 16 | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 260 |
111 | 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 135 | 151 | |
Total Assets | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 | -28 | |
-24 | -9 | -38 | -36 | -11 | -19 | -20 | -37 | -40 | -5 | -33 | 23 | |
-2 | -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 | 0 | |
Net Cash Flow | -5 | 1 | 12 | -10 | 15 | -4 | 0 | -2 | -1 | -1 | 4 | -5 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 54 | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 | 30 | 29 |
Inventory Days | 191 | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 149 | 126 | 201 |
Days Payable | 135 | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 | 98 | 118 |
Cash Conversion Cycle | 111 | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 | 58 | 112 |
Working Capital Days | 21 | 27 | 25 | 24 | 10 | 21 | 18 | -10 | -34 | 14 | -13 | 6 |
ROCE % | 18% | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% | 28% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Sep - Newspaper Publication on 06.09.2025 regarding Postal Ballot Notice dated 21.08.2025 in English Newspaper Financial Express all editions and Bengali Newspaper Aajkal
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 5 Sep
- Shareholder Meeting / Postal Ballot-Outcome of AGM 30 Aug
-
Announcement under Regulation 30 (LODR)-Change in Directorate
21 Aug - Dr. Monjori Mitra reappointed Independent Director 24Aug2025–23Aug2030; shareholder postal-ballot; e-voting cut-off 29Aug2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Aug - Newspaper publication of Postal Ballot Notice and E-Voting Information
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.